​

Connect Biopharma (CNTB) Stock Forecast, Price Target & Predictions

OverviewOwnershipChart

CNTB Stock Forecast

Connect Biopharma (CNTB) stock forecast, based on 4 Wall Street analysts, predicts a 12-month average price target of $1.50, with a high of $1.50 and a low of $1.50. This represents a 76.47% increase from the last price of $0.85.

High: $1.5 Avg: $1.5 Low: $1.5 Last Closed Price: $0.85

CNTB Stock Rating

Connect Biopharma stock's rating consensus is Buy, based on 4 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 3 Buy (75.00%), 1 Hold (25.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 4 0 1 3 Strong Sell Sell Hold Buy Strong Buy

CNTB Price Target Upside V Benchmarks

TypeNameUpside
StockConnect Biopharma76.47%
SectorHealthcare Stocks 24.81%
IndustryBiotech Stocks 65.78%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$0.85$0.85$0.85
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 2511---2
May, 2511---2
Apr, 2511---2
Mar, 2511---2
Feb, 2511---2
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 05, 2022Joseph CatanzaroPiper Sandler$1.50$0.8282.93%76.47%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 06, 2024H.C. WainwrightBuyBuyhold
Apr 17, 2024H.C. WainwrightBuyBuyhold
Jun 18, 2022Cantor FitzgeraldOverweightinitialise

Financial Forecast

EPS Forecast

$-6 $-5 $-4 $-3 $-2 $-1 $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.08$-0.28----
Avg Forecast$-5.47$-1.42$-5.30$-2.72$-0.07$-1.36
High Forecast$-5.47$-1.42$-5.30$-2.72$-0.07$-1.36
Low Forecast$-5.47$-1.42$-5.30$-2.72$-0.07$-1.36
Surprise %-80.26%-80.28%----

Revenue Forecast

$0 $90M $180M $270M $360M $450M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported-$26.03M----
Avg Forecast$149.90M$170.76M$282.56M$221.75M$444.94M$370.54M
High Forecast$149.90M$170.76M$282.56M$221.75M$445.80M$370.54M
Low Forecast$149.90M$170.76M$282.56M$221.75M$444.07M$370.54M
Surprise %--84.75%----

Net Income Forecast

$-350M $-280M $-210M $-140M $-70M $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-59.50M$-15.63M----
Avg Forecast$-301.07M$-78.04M$-291.79M$-149.69M$-4.10M$-74.84M
High Forecast$-301.07M$-78.04M$-291.79M$-149.69M$-4.10M$-74.84M
Low Forecast$-301.07M$-78.04M$-291.79M$-149.69M$-4.10M$-74.84M
Surprise %-80.24%-79.97%----

CNTB Forecast FAQ

Is Connect Biopharma stock a buy?

Connect Biopharma stock has a consensus rating of Buy, based on 4 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 3 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Connect Biopharma is a favorable investment for most analysts.

What is Connect Biopharma's price target?

Connect Biopharma's price target, set by 4 Wall Street analysts, averages $1.5 over the next 12 months. The price target range spans from $1.5 at the low end to $1.5 at the high end, suggesting a potential 76.47% change from the previous closing price of $0.85.

How does Connect Biopharma stock forecast compare to its benchmarks?

Connect Biopharma's stock forecast shows a 76.47% upside, outperforming the average forecast for the healthcare stocks sector (24.81%) and outperforming the biotech stocks industry (65.78%).

What is the breakdown of analyst ratings for Connect Biopharma over the past three months?

  • June 2025: 50.00% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • May 2025: 50.00% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • April 2025: 50.00% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Connect Biopharma’s EPS forecast?

Connect Biopharma's average annual EPS forecast for its fiscal year ending in December 2025 is $-5.3, marking a 1792.86% increase from the reported $-0.28 in 2024. Estimates for the following years are $-2.72 in 2026, $-0.07 in 2027, and $-1.36 in 2028.

What is Connect Biopharma’s revenue forecast?

Connect Biopharma's average annual revenue forecast for its fiscal year ending in December 2025 is $282.56M, reflecting a 985.37% increase from the reported $26.03M in 2024. The forecast for 2026 is $221.75M, followed by $444.94M for 2027, and $370.54M for 2028.

What is Connect Biopharma’s net income forecast?

Connect Biopharma's net income forecast for the fiscal year ending in December 2025 stands at $-292M, representing an 1767.13% increase from the reported $-15.628M in 2024. Projections indicate $-150M in 2026, $-4.099M in 2027, and $-74.843M in 2028.